Sumanta Kumar Pal, M.D.

  • Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research
  • Co-director, Kidney Cancer Program
  • Medical Oncologist

Sumanta Kumar Pal, M.D.

Clinical Specialties
  • Medical Oncology
Areas of Expertise
  • Urology and Urologic Oncology
  • Kidney Cancer
  • Bladder Cancer
  • Prostate Cancer
Research Focus
  • Urology and Urologic Oncology
Other Languages Spoken
  • Spanish
Sumanta (Monty) Kumar Pal, M.D., is an internationally recognized leader in the area of genitourinary cancers, including kidney, bladder, and prostate cancer. He is the Co-director of City of Hope's Kidney Cancer Program and is the head of the kidney and bladder cancer disease team at the institution.

Dr. Pal entered college at the age of 13 and began medical school at University of California, Los Angeles at the age of 17. After completing his residency training at University of California, Los Angeles, Dr. Pal completed a fellowship program in medical oncology at City of Hope's comprehensive cancer center where he remains on faculty since 2009.

Over that span of time, he has published more than 200 peer-reviewed articles that have been featured in prominent journals including The Journal of Clinical Oncology, Lancet Oncology, Cancer Cell, and European Urology.

Dr. Pal holds patents for new drugs currently under development in prostate cancer and also maintains one of the largest portfolios of clinical trials for kidney and bladder cancer research on the west coast. He developed an integrated program that focuses heavily on collaborations with basic science researchers at Beckman Research Institute of City of Hope and urologists in the Department of Surgery. Ultimately, Dr. Pal’s goal is to stimulate collaborative research across multiple departments in order to discover novel therapeutic approaches for our currently incurable diseases. He has also worked to push the boundaries of personalized medicine in genitourinary cancers, with several seminal publications in rare genitourinary cancers that describe unique therapeutic targets.
 
Dr. Pal sits on the Editorial Board for Clinical Genitourinary Cancer and Kidney Cancer and is a reviewer for multiple journals including The Journal of Clinical Oncology, The Journal of Urology, European Urology, and many others. Dr. Pal has received grants from the National Institute of Health, the Comprehensive Cancer Network, the Southwest Oncology Group, and multiple other leading entities in support of his formidable research.
 
  • 2016 - present, Associate Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
  • 2009 - 2016, Assistant Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
  • 2009 - present, Co-director, Kidney Cancers Program, City of Hope, Duarte, CA
  • Bladder Cancer
  • Kidney Cancer
  • Prostate Cancer
  • Urology and Urologic Cancers

Duarte

1500 East Duarte Road, Duarte, CA, 91010

Get Directions

Phone :  626-256-4673

Degrees

  • 2003, David Geffen School of Medicine at UCLA, Los Angeles, CA, M.D.
  • 1998, California State University, Los Angeles Early Entrance Program, College in lieu of high school (program initiated at age 13), Magna Cum Laude, B.Sc.

Fellowship

  • 2006 - 2009, Fellowship in Hematology/Oncology, City of Hope/Harbor-UCLA Medical Center, Los Angeles, CA

Residency

  • 2003 - 2006, Residency in Internal Medicine, UCLA Medical Center, Los Angeles, CA
The Perfect Marriage of Patient Care and Scientific Research
The Perfect Marriage of Patient Care and Scientific Research

Dr. Pal - Connecting Patient Care with Scientific Research

March 31, 2017
  • Luke JJ, Pal SK. Further evidence to support judicious use of antibiotics in patients with cancer. Ann Oncol. 2018 Apr 24. doi: 10.1093/annonc/mdy153. [Epub ahead of print] PubMed PMID: 29688263.
  • Pal SK, Bergerot P, Dizman N, Bergerot C, Adashek J, Madison R, Chung JH, Ali SM, Jones JO, Salgia R. Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. Eur Urol. 2018 Apr 20. pii: S0302-2838(18)30250-1. doi: 10.1016/j.eururo.2018.03.032. [Epub ahead of print] PubMed PMID: 29685646.
  • Yin M, Grivas P, Emamekhoo H, Mendiratta P, Ali S, Hsu J, Vasekar M, Drabick JJ, Pal S, Joshi M. ATM/RB1 mutations predict shorter overall survival in urothelial cancer. Oncotarget. 2018 Mar 30;9(24):16891-16898. doi: 10.18632/oncotarget.24738. eCollection 2018 Mar 30. PubMed PMID: 29682192; PubMed Central PMCID: PMC5908293.
  • de Velasco G, Wankowicz SA, Madison R, Ali SM, Norton C, Duquette A, Ross JS, Bossé D, Lalani AA, Miller VA, Stephens PJ, Young L, Hakimi AA, Signoretti S, Pal SK, Choueiri TK. Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. Br J Cancer. 2018 Apr 20. doi: 10.1038/s41416-018-0064-3. [Epub ahead of print] PubMed PMID: 29674707.
  • Gong J, Pan K, Fakih M, Pal S, Salgia R. Value-based genomics. Oncotarget. 2018 Jan 30;9(21):15792-15815. doi: 10.18632/oncotarget.24353. eCollection 2018 Mar 20. Review. PubMed PMID: 29644010; PubMed Central PMCID: PMC5884665.
  • Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer. 2018 Mar 8. doi: 10.1002/cncr.31314. [Epub ahead of print] PubMed PMID: 29517810.
  • Tannir NM, Pal SK, Atkins MB. Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review. Oncologist. 2018 Feb 27. pii: theoncologist.2017-0534. doi: 10.1634/theoncologist.2017-0534. [Epub ahead of print] Review. PubMed PMID: 29487224.
  • Pal SK, Hoffman-Censits J, Zheng H, Kaiser C, Tayama D, Bellmunt J. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States. Eur Urol. 2018 May;73(5):800-806. doi: 10.1016/j.eururo.2018.02.010. Epub 2018 Feb 22. PubMed PMID: 29478735.
  • Copeland BT, Pal SK, Bolton EC, Jones JO. The androgen receptor malignancy shift in prostate cancer. Prostate. 2018 May;78(7):521-531. doi: 10.1002/pros.23497. Epub 2018 Feb 23. Review. PubMed PMID: 29473182.
  • Bergerot PG, Hahn AW, Bergerot CD, Jones J, Pal SK. The Role of Circulating Tumor DNA in Renal Cell Carcinoma. Curr Treat Options Oncol. 2018 Feb 20;19(2):10. doi: 10.1007/s11864-018-0530-4. Review. PubMed PMID: 29464405.
  • Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pal SK, Hsu J, Appleman LJ, Ornstein MC, Gilligan T, Grivas P, Garcia JA, Rini BI. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. J Immunother Cancer. 2018 Jan 29;6(1):9. doi: 10.1186/s40425-018-0319-9. PubMed PMID: 29378660; PubMed Central PMCID: PMC5789686.
  • Cella D, Escudier B, Tannir NM, Powles T, Donskov F, Peltola K, Schmidinger M, Heng DYC, Mainwaring PN, Hammers HJ, Lee JL, Roth BJ, Marteau F, Williams P, Baer J, Mangeshkar M, Scheffold C, Hutson TE, Pal S, Motzer RJ, Choueiri TK. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. J Clin Oncol. 2018 Mar 10;36(8):757-764. doi: 10.1200/JCO.2017.75.2170. Epub 2018 Jan 29. PubMed PMID: 29377755.
  • Zhu J, Armstrong AJ, Friedlander TW, Kim W, Pal SK, George DJ, Zhang T. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. J Immunother Cancer. 2018 Jan 25;6(1):4. doi: 10.1186/s40425-018-0314-1. Review. PubMed PMID: 29368638; PubMed Central PMCID: PMC5784676.
  • Priceman SJ, Gerdts EA, Tilakawardane D, Kennewick KT, Murad JP, Park AK, Jeang B, Yamaguchi Y, Yang X, Urak R, Weng L, Chang WC, Wright S, Pal S, Reiter RE, Wu AM, Brown CE, Forman SJ. Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. Oncoimmunology. 2017 Oct 16;7(2):e1380764. doi: 10.1080/2162402X.2017.1380764. eCollection 2018. PubMed PMID: 29308300; PubMed Central PMCID: PMC5749625.
  • Pal SK, He M, Chen L, Yang L, Pillai R, Twardowski P, Hsu J, Kortylewski M, Jones JO. Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide. Urol Oncol. 2018 Apr;36(4):162.e1-162.e6. doi: 10.1016/j.urolonc.2017.12.006. Epub 2017 Dec 27. PubMed PMID: 29289429; PubMed Central PMCID: PMC5899661.
  • Bergerot PG, Bergerot CD, Dizman N, Zequi S, Fay A, Dara Y, Maia MC, Cotta BN, Gonçalves EP, Formiga MN, Tariki MS, Clavijo DA, Choueiri TK, Lopes G, Pal SK. Assessment of Treatment Patterns for Metastatic Renal Cell Carcinoma in Brazil. J Glob Oncol. 2017 Dec 27:JGO1700113. doi: 10.1200/JGO.17.00113. [Epub ahead of print] PubMed PMID: 29281478.
  • Pal SK, Patel J, He M, Foulk B, Kraft K, Smirnov DA, Twardowski P, Kortylewski M, Bhargava V, Jones JO. Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC). Cancer. 2018 Mar 15;124(6):1216-1224. doi: 10.1002/cncr.31161. Epub 2017 Dec 19. PubMed PMID: 29266182.
  • Maia MC, Adashek J, Bergerot P, Almeida L, Dos Santos SF, Pal SK. Current systemic therapies for metastatic renal cell carcinoma in older adults: A comprehensive review. J Geriatr Oncol. 2017 Dec 15. ii: S1879-4068(17)30250-3. doi: 10.1016/j.jgo.2017.11.011. [Epub ahead of print] Review. PubMed PMID: 29249644.
  • Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, Domingo-Domenech J, Oh WK, Akers N, Losic B, Gnjatic S, Schadt EE, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov AV. Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. Eur Urol. 2018 May;73(5):751-759. doi: 10.1016/j.eururo.2017.12.001. Epub 2017 Dec 13. PubMed PMID: 29248319.
  • Necchi A, Pond GR, Pal SK, Agarwal N, Bowles DW, Plimack ER, Yu EY, Ladoire S, Baniel J, Crabb S, Niegisch G, Srinivas S, Berthold DR, Rosenberg JE, Powles T, Bamias A, Harshman LC, Bellmunt J, Galsky MD; Retrospective International Study of Invasive/Advanced Cancer of the Urothelium Group. Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. Clin Genitourin Cancer. 2018 Apr;16(2):e483-e490. doi: 10.1016/j.clgc.2017.10.012. Epub 2017 Nov 1. PubMed PMID: 29158079.
  • Maia MC, Grivas P, Agarwal N, Pal SK. Circulating Tumor DNA in Bladder Cancer: Novel Applications and Future Directions. Eur Urol. 2018 Apr;73(4):541-542. doi: 10.1016/j.eururo.2017.10.011. Epub 2017 Oct 31. PubMed PMID: 29097099.
  • Ross JS, Ali SM, Fasan O, Block J, Pal S, Elvin JA, Schrock AB, Suh J, Nozad  S, Kim S, Jeong Lee H, Sheehan CE, Jones DM, Vergilio JA, Ramkissoon S, Severson  E, Daniel S, Fabrizio D, Frampton G, Miller VA, Stephens PJ, Gay LM. ALK Fusions  in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy. Oncologist. 2017 Dec;22(12):1444-1450. doi: 10.1634/theoncologist.2016-0488. Epub 2017 Oct 27. PubMed PMID: 29079636; PubMed Central PMCID: PMC5728036.
  • Vogelzang NJ, Pal SK, Ghate SR, Swallow E, Li N, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis. Adv Ther. 2017 Nov;34(11):2452-2465. doi: 10.1007/s12325-017-0628-2. Epub 2017 Oct 26. PubMed PMID: 29076108; PubMed Central PMCID: PMC5702370.
  • Hahn AW, Pal SK, Agarwal N. HSD3B1-A Predictive Biomarker in Advanced Prostate Cancer. JAMA Oncol. 2018 Apr 1;4(4):562-563. doi: 10.1001/jamaoncol.2017.3158. PubMed PMID: 29049481.
  • Dizman N, Maia MC, Pal SK. Cytoreductive nephrectomy: A medical oncologist's  perspective. Urol Oncol. 2017 May;35(5):180-182. doi: 10.1016/j.urolonc.2017.03.018. Epub 2017 Apr 18. PubMed PMID: 29037531.
  • Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs  TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA,  Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Oct;15(10):1240-1267. doi: 10.6004/jnccn.2017.0156. PubMed PMID: 28982750.
  • Yuan Y, Yost SE, Yim J, Yuan YC, Solomon NM, Mambetsariev I, Pal S, Frankel P, Salgia R, Neuhausen SL, Mortimer J. Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience. Oncotarget. 2017 Sep 22;8(37):62817. doi: 10.18632/oncotarget.20632. eCollection 2017 Sep 22. PubMed PMID: 28977992; PubMed Central PMCID: PMC5617552.
  • Bergerot P, Agarwal N, Pal SK, Jones J. Sarcomatoid Renal Cell Carcinoma: The Apple Doesn't Fall Far from the Tree. Clin Cancer Res. 2017 Nov 1;23(21):6381-6383. doi: 10.1158/1078-0432.CCR-17-2039. Epub 2017 Sep 14. PubMed PMID: 28912138.
  • Chenam A, Parihar JS, Ruel N, Pal S, Avila Y, Yamzon J, Lau C, Yuh B. Lymph node-positive prostate cancer after robotic prostatectomy and extended pelvic lymphadenectomy. J Robot Surg. 2017 Sep 13. doi: 10.1007/s11701-017-0751-8. [Epub ahead of print] PubMed PMID: 28905289.
  • Boustani J, Bertaut A, Galsky MD, Rosenberg JE, Bellmunt J, Powles T, Recine F, Harshman LC, Chowdhury S, Niegisch G, Yu EY, Pal SK, De Giorgi U, Crabb SJ, Caubet M, Balssa L, Milowsky MI, Ladoire S, Créhange G; Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Acta Oncol. 2018 Apr;57(4):491-497. doi: 10.1080/0284186X.2017.1369565. Epub 2017 Aug 30. PubMed PMID: 28853615.
  • Dizman N, Bergerot P, Bergerot C, Lanman RB, Raymond VM, Banks KC, Jones J, Pal SK. Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile. Eur Urol. 2018 Feb;73(2):308-310. doi: 10.1016/j.eururo.2017.08.006. Epub 2017 Aug 24. PubMed PMID: 28844598.
  • Dorff TB, Longmate JA, Pal SK, Stadler WM, Fishman MN, Vaishampayan UN, Rao A, Pinksi JK, Hu JS, Quinn DI, Lara PN Jr. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer. 2017 Dec 1;123(23):4566-4573. doi: 10.1002/cncr.30942. Epub 2017 Aug 22. PubMed PMID: 28832978; PubMed Central PMCID: PMC5726867.
  • Wentink MQ, Verheul HMW, Pal SK, George S, Voortman J, Danchaivijitr P, Adelaiye R, Poslinski D, Groman A, Hutson A, Pili R. Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma. Clin Genitourin Cancer. 2017 Jul 14. pii: S1558-7673(17)30201-X. doi: 10.1016/j.clgc.2017.07.004. [Epub ahead of print] PubMed PMID: 28781191.
  • Maia MC, Yang ES, Agarwal N, Pal SK. A step towards predicting checkpoint inhibitor response in kidney cancer. Lancet Oncol. 2017 Aug;18(8):982-983. doi: 10.1016/S1470-2045(17)30533-8. Epub 2017 Jul 26. PubMed PMID: 28759367.
  • Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K; Young Academic Urologists-Urothelial Carcinoma Group-European Association of Urology and the Retrospective International Study of Invasive/Advanced Cancer of the Urothelium group. Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. Eur Urol Focus. 2017 Jun 3. pii: S2405-4569(17)30125-6. doi: 10.1016/j.euf.2017.05.006. [Epub ahead of print] PubMed PMID: 28753897; PubMed Central PMCID: PMC5712487.
  • Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthold DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD; Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. Eur Urol Focus. 2017 Mar 31. pii: S2405-4569(17)30079-2. doi: 10.1016/j.euf.2017.03.011. [Epub ahead of print] PubMed PMID: 28753879; PubMed Central PMCID: PMC5626651.
  • Ho TH, Choueiri TK, Wang K, Karam JA, Chalmers Z, Frampton G, Elvin JA, Johnson A, Liu X, Lin Y, Joseph RW, Stanton ML, Miller VA, Stephens PJ, Ross JS, Ali SM, Pal SK. Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. Eur Urol Focus. 2016 Jun;2(2):204-209. doi: 10.1016/j.euf.2015.11.007. Epub 2015 Dec 9. PubMed PMID: 28723536.
  • Maia MC, Bergerot P, Pal SK. Case Discussion: Systemic Therapy for Metastatic Renal Cell Carcinoma. Eur Urol Focus. 2016 Dec 15;2(6):579-581. doi: 10.1016/j.euf.2017.02.008. Epub 2017 Mar 1. PubMed PMID: 28723488.
  • Giles RH, Choueiri TK, Heng DY, Albiges L, Hsieh JJ, Linehan WM, Pal S, Maskens D, Paseman B, Jonasch E, Malouf G, Molina AM, Pickering L, Shuch B, Srinivas S, Srinivasan R, Tannir NM, Bex A. Recommendations for the Management of Rare Kidney Cancers. Eur Urol. 2017 Dec;72(6):974-983. doi: 10.1016/j.eururo.2017.06.040. Epub 2017 Jul 16. Review. PubMed PMID: 28720391.
  • Pal SK, Pham A, Vuong W, Liu X, Lin Y, Ruel N, Yuh BE, Chan K, Wilson T, Lerner SP, McConkey D, Jove R, Liang W. Prognostic Significance of Neutrophilic Infiltration in Benign Lymph Nodes in Patients with Muscle-invasive Bladder Cancer. Eur Urol Focus. 2017 Feb;3(1):130-135. doi: 10.1016/j.euf.2016.03.003. Epub 2016 Mar 25. PubMed PMID: 28720358.
  • Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, Voss MH, Sharma P, Pal SK, Razak ARA, Kollmannsberger C, Heng DYC, Spratlin J, McHenry MB, Amin A. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. J Clin Oncol. 2017 Dec 1;35(34):3851-3858. doi: 10.1200/JCO.2016.72.1985. Epub 2017 Jul 5. PubMed PMID: 28678668.
  • Hahn AW, Gill DM, Pal SK, Agarwal N. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy. 2017 Jun;9(8):681-692. doi: 10.2217/imt-2017-0024. Review. PubMed PMID: 28653573.
  • Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DYC, Powles T, Frigault MM, Clark EA, Handzel AA, Gardner H, Morgan S, Albiges L, Pal SK. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. J Clin Oncol. 2017 Sep 10;35(26):2993-3001. doi: 10.1200/JCO.2017.72.2967. Epub 2017 Jun 23. PubMed PMID: 28644771.
  • Elix C, Pal SK, Jones JO. The role of peroxisome proliferator-activated receptor gamma in prostate cancer. Asian J Androl. 2017 Jun 9. doi: 10.4103/aja.aja_15_17. [Epub ahead of print] Review. PubMed PMID: 28597850.
  • Pal SK, Ali SM, Yakirevich E, Geynisman DM, Karam JA, Elvin JA, Frampton GM,  Huang X, Lin DI, Rosenzweig M, Lipson D, Stephens PJ, Ross JS, Miller VA, Agarwal N, Shuch B, Choueiri TK, Chung JH. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. Eur Urol. 2018 Jan;73(1):71-78. doi: 10.1016/j.eururo.2017.05.033. Epub 2017 Jun 4. PubMed PMID: 28592388.
  • Zhang T, Gong J, Maia MC, Pal SK. Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma. Am Soc Clin Oncol Educ Book. 2017;37:337-342. doi: 10.14694/EDBK_175572. PubMed PMID: 28561708.
  • Won H, Moreira D, Gao C, Duttagupta P, Zhao X, Manuel E, Diamond D, Yuan YC,  Liu Z, Jones J, D'Apuzzo M, Pal S, Kortylewski M. TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs. J Leukoc Biol. 2017 Aug;102(2):423-436. doi: 10.1189/jlb.3MA1016-451RR. Epub 2017 May 22. PubMed PMID: 28533357; PubMed Central PMCID: PMC5505743.
  • Gill DM, Sonpavde G, Pal SK, Agarwal N. Which checkpoint inhibitor? An embarrassment of riches for bladder cancer. Immunotherapy. 2017 May;9(6):463-466. doi: 10.2217/imt-2017-0033. PubMed PMID: 28472906.
  • Bailey EB, Merriman J, Maughan B, Poole A, Tantravahi SK, Agarwal AM, Batten  JA, Patel SB, Pal SK, Stenehjem DD, Agarwal N. Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients  with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors. J Oncol Pharm Pract. 2018 Apr;24(3):190-197. doi: 10.1177/1078155217693426. Epub 2017 Feb 20. PubMed PMID: 28436250.
  • Hahn AW, Gill DM, Maughan B, Agarwal A, Arjyal L, Gupta S, Streeter J, Bailey E, Pal SK, Agarwal N. Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. Oncotarget. 2017 May 16;8(20):33614-33620. doi: 10.18632/oncotarget.16833. PubMed PMID: 28431395; PubMed Central PMCID: PMC5464894.
  • American Society of Clinical Oncology (ASCO) (2006- present)
      Cancer Communications Committee, Chair (2017-present)
      Leadership Development Program (2016-present)
      Social Media Working Group (2015-present)
      Genitourinary Cancers Committee (2013-present)
      HER2-Positive Breast Cancer Committee (2012-2013)
  • National Comprehensive Cancer Network Bladder Cancer Committee (2010-present)
  • Kidney Cancer Association Scientific Program Committee, Chair (2015-present)
  • Society of Immunotherapy for Cancer (SITC) Patient Meeting, Chair (2015-present)
  • Society of Urologic Oncology (SUO) Prostate Cancer Committee, Chair (2015-present)
Back To Top